ALS Therapeutic Compounds Selected by Multi-Ethnic Genomic Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective therapeutic method for amyotrophic lateral sclerosis (ALS), and existing clinical trials face challenges due to the disease's diversity in progression and lack of established genome drug discovery methodologies, particularly for multiple ethnic groups.
Innovation Solution
Identification of ALS risk genotypes through genome-wide association studies and overlap enrichment analysis, leading to the use of compounds like paclitaxel, docetaxel, carfilzomib, olaparib, and nicotinamide to enhance neurite length of motor neurons, thereby developing a prophylactic and therapeutic agent for ALS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical trials are conducted for ALS treatment, then therapeutic effectiveness is evaluated, but the diversity of disease progression makes it difficult to analyze results and establish effective treatment
Solution Approach 1:
The patent changes the approach from evaluating overall disease progression to measuring specific molecular parameters (neurite length) as biomarkers. This allows for more reliable analysis of treatment effects despite the diversity in clinical progression patterns among ALS patients.
Solution Approach 2:
The patent replaces complex clinical trial analysis with molecular-level measurements. Instead of relying on subjective clinical assessments that are difficult to standardize, the invention uses objective molecular markers (neurite length) to evaluate treatment effectiveness.
2Productivity
If genome-wide association studies are performed for multiple ethnic groups, then more effective therapeutic drug candidates can be identified, but no established methodology exists for genome drug discovery across multiple races
Solution Approach 1:
The patent performs preliminary genome-wide association studies across multiple ethnic groups to identify risk genotypes before moving to drug development. This preliminary genetic characterization establishes a foundation that simplifies subsequent drug discovery processes and enables more efficient candidate identification.
Solution Approach 2:
The patent creates a universal approach for genome drug discovery that can be applied across multiple ethnic groups. By establishing a multi-ethnic GWAS framework, the methodology becomes universally applicable for identifying therapeutic candidates in diverse populations, eliminating the need for separate studies for each ethnic group.
3Reliability
If new therapeutic compounds are developed for ALS, then treatment effectiveness may be improved, but development time and cost are significant barriers
Solution Approach 1:
The patent uses neurite length as an intermediary biomarker to quickly assess treatment effects in preclinical models. This intermediary measure provides rapid feedback on compound effectiveness without requiring lengthy clinical trials, thereby reducing overall development time while maintaining reliability of effectiveness assessment.
Solution Approach 2:
The patent implements feedback mechanisms through biomarker measurement (neurite length) that provide early indication of treatment response. This feedback allows for rapid iteration and optimization of compound candidates, significantly reducing the time needed to identify effective treatments compared to traditional development approaches.
Data Source
Figure 1(a)~2(d)
Figure 3(a)~4(d)
Figure 5(a)~5(d)
AI summary
An object of the present invention is to provide a prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis. A prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis, comprising at least one compound selected from the group consisting of paclitaxel, docetaxel, carfilzomib, olaparib, and nicotinamide.